DeepMed Research

Georgetown University

🇬🇹Guatemala

Country: 🇬🇹Guatemala

Ownership: Private

Established: 1789-01-23

Employees: 5K

Market Cap: -

Website: http://www.georgetown.edu

Clinical Trials

PathToScale: An Implementation Evaluation

Recruiting

Conditions: Oral Pre-exposure Prophylaxis (PrEP)
Long-acting Injectable Cabotegravir for PrEP

First Posted Date: 2024-03-19

Last Posted Date: 2024-03-29

Lead Sponsor: Georgetown University

Target Recruit Count: 9900

Registration Number: NCT06319105

Locations: 🇲🇼
Community Health Science Unit, Lilongwe, Malawi

Leveraging Telehealth to Improve Oral Health Among Cancer Survivors

Not Applicable

Recruiting

Conditions: Oral Mucositis
Periodontal Diseases
Cancer

Interventions: Behavioral: Telehealth Intervention (THI)

First Posted Date: 2024-03-18

Last Posted Date: 2025-03-13

Lead Sponsor: Georgetown University

Target Recruit Count: 100

Registration Number: NCT06315855

Locations: 🇺🇸
Georgetown Lombardi Office of Minority Health, Washington, District of Columbia, United States

Tobacco Education and Lung Health Study (TEAL)

Phase 3

Recruiting

Conditions: Smoking Cessation

Interventions: Behavioral: E-Referral to the Tobacco Quitline
Behavioral: Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention

First Posted Date: 2024-03-04

Last Posted Date: 2024-03-06

Lead Sponsor: Georgetown University

Target Recruit Count: 1188

Registration Number: NCT06290869

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

Phase 2

Recruiting

Conditions: Thymic Carcinoma
Thymoma

Interventions: Drug: Sacituzumab govitecan-hziy

First Posted Date: 2024-02-08

Last Posted Date: 2025-03-12

Lead Sponsor: Georgetown University

Target Recruit Count: 18

Registration Number: NCT06248515

Locations: 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

Phase 2

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: MGC018

First Posted Date: 2024-01-29

Last Posted Date: 2025-03-25

Lead Sponsor: Georgetown University

Target Recruit Count: 17

Registration Number: NCT06227546

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
Hackensack Meridian Health, John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States

Connect to Baby: A Pilot Study of a Parenting and Coparenting Program

Not Applicable

Recruiting

Conditions: Parenting

Interventions: Behavioral: Connect to Baby

First Posted Date: 2023-12-22

Last Posted Date: 2023-12-22

Lead Sponsor: Georgetown University

Target Recruit Count: 200

Registration Number: NCT06179576

Locations: 🇺🇸
Child Development and Social Policy Lab, Washington, District of Columbia, United States

Does Social Media Impact Adolescent Mental Health?

Not Applicable

Recruiting

Conditions: Mental Health

Interventions: Behavioral: Restricted Social Media

First Posted Date: 2023-09-22

Last Posted Date: 2025-03-14

Lead Sponsor: Georgetown University

Target Recruit Count: 500

Registration Number: NCT06049888

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States

Daratumumab for Polyneuropathy Associated With MGUS

Phase 2

Recruiting

Conditions: Monoclonal Gammopathy of Undetermined Significance
Peripheral Neuropathy

Interventions: Drug: Daratumumab and hyaluronidase-fihj

First Posted Date: 2023-09-21

Last Posted Date: 2025-03-24

Lead Sponsor: Georgetown University

Target Recruit Count: 20

Registration Number: NCT06046287

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Phase 2

Withdrawn

Conditions: Borderline Resectable Carcinoma
Biliary Tract Cancer

Interventions: Drug: Durvalumab
Drug: Tremelimumab
Drug: Gemcitabine
Drug: Cisplatin
Procedure: Surgical Resection

First Posted Date: 2023-08-30

Last Posted Date: 2024-11-12

Lead Sponsor: Georgetown University

Target Recruit Count: 28

Registration Number: NCT06017297

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States

Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Withdrawn

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Nab paclitaxel
Drug: Proglumide Dose level 1
Drug: Proglumide Dose level 2

First Posted Date: 2023-08-30

Last Posted Date: 2023-10-25

Lead Sponsor: Georgetown University

Registration Number: NCT06017323

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy